Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 420

1.

Thrombopoietin receptor agonists in hereditary thrombocytopenias.

Rodeghiero F, Pecci A, Balduini CL.

J Thromb Haemost. 2018 Sep;16(9):1700-1710. doi: 10.1111/jth.14217. Epub 2018 Jul 27. Review.

PMID:
29956472
2.

The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B2 assay as an evaluation tool of different aspirin dosing regimens in the clinical setting.

De Stefano V, Rocca B, Tosetto A, Soldati D, Petrucci G, Beggiato E, Bertozzi I, Betti S, Carli G, Carpenedo M, Cattaneo D, Cavalca V, Dragani A, Elli E, Finazzi G, Iurlo A, Lanzarone G, Lissandrini L, Palandri F, Paoli C, Rambaldi A, Ranalli P, Randi ML, Ricco A, Rossi E, Ruggeri M, Specchia G, Timillero A, Turnu L, Vianelli N, Vannucchi AM, Rodeghiero F, Patrono C.

Blood Cancer J. 2018 Jun 1;8(6):49. doi: 10.1038/s41408-018-0078-3.

3.

Fifth Åland Island conference on von Willebrand disease.

Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen MH, Croteau SE, von Depka M, Federici AB, Goodeve A, Goudemand J, Mannucci PM, Mourik M, Önundarson PT, Rodeghiero F, Szántó T, Windyga J.

Haemophilia. 2018 May;24 Suppl 4:5-19. doi: 10.1111/hae.13475.

PMID:
29687935
4.

A comparative prospective observational study of children and adults with immune thrombocytopenia: 2-year follow-up.

Schifferli A, Holbro A, Chitlur M, Coslovsky M, Imbach P, Donato H, Elalfy M, Graciela E, Grainger J, Holzhauer S, Riccheri C, Rodeghiero F, Ruggeri M, Tamary H, Uglova T, Wu R, Kühne T; Intercontinental Cooperative ITP Study Group (ICIS).

Am J Hematol. 2018 Jun;93(6):751-759. doi: 10.1002/ajh.25086. Epub 2018 Mar 30.

PMID:
29516627
5.

A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP.

Rodeghiero F.

Br J Haematol. 2018 Apr;181(2):183-195. doi: 10.1111/bjh.15090. Epub 2018 Feb 26. Review.

PMID:
29479668
7.

ITP and thrombosis: an intriguing association.

Rodeghiero F.

Blood Adv. 2017 Nov 14;1(24):2280. doi: 10.1182/bloodadvances.2017007989. eCollection 2017 Nov 14. No abstract available.

8.

Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.

Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D'adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R.

Am J Hematol. 2018 Jan;93(1):58-64. doi: 10.1002/ajh.24935. Epub 2017 Nov 9.

PMID:
28983953
9.

A hit to current "hit" wisdom: A century later, it's time for a change.

Rodeghiero F.

Am J Hematol. 2017 Aug;92(8):727-729. doi: 10.1002/ajh.24789. Epub 2017 Jun 5. No abstract available.

10.

Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia.

Cines DB, Wasser J, Rodeghiero F, Chong BH, Steurer M, Provan D, Lyons R, Garcia-Chavez J, Carpenter N, Wang X, Eisen M.

Haematologica. 2017 Aug;102(8):1342-1351. doi: 10.3324/haematol.2016.161968. Epub 2017 Apr 14.

11.

Beyond immune thrombocytopenia: the evolving role of thrombopoietin receptor agonists.

Rodeghiero F, Carli G.

Ann Hematol. 2017 Sep;96(9):1421-1434. doi: 10.1007/s00277-017-2953-6. Epub 2017 Mar 8. Review.

PMID:
28275823
12.

Generation of mesenchymal stromal cells from cord blood: evaluation of in vitro quality parameters prior to clinical use.

Amati E, Sella S, Perbellini O, Alghisi A, Bernardi M, Chieregato K, Lievore C, Peserico D, Rigno M, Zilio A, Ruggeri M, Rodeghiero F, Astori G.

Stem Cell Res Ther. 2017 Jan 24;8(1):14. doi: 10.1186/s13287-016-0465-2.

13.

Heterogeneity of Specific CD4+ and CD8+ T Cells Stimulated by CMV pp65 and IE1 Antigens.

Albiero E, Amati E, Baumeister E, Einsele H, Grigoleit GU, Rodeghiero F.

J Immunother. 2016 Nov/Dec;39(9):329-342.

PMID:
27631893
14.

Platelet lysate as a substitute for animal serum for the ex-vivo expansion of mesenchymal stem/stromal cells: present and future.

Astori G, Amati E, Bambi F, Bernardi M, Chieregato K, Schäfer R, Sella S, Rodeghiero F.

Stem Cell Res Ther. 2016 Jul 13;7(1):93. doi: 10.1186/s13287-016-0352-x. Review.

15.

Health-related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease.

Efficace F, Mandelli F, Fazi P, Santoro C, Gaidano G, Cottone F, Borchiellini A, Carpenedo M, Simula MP, Di Giacomo V, Bergamaschi M, Vincelli ID, Rodeghiero F, Ruggeri M, Scaramucci L, Rambaldi A, Cascavilla N, Forghieri F, Petrungaro A, Ditonno P, Caocci G, Cirrincione S, Mazzucconi MG.

Am J Hematol. 2016 Oct;91(10):995-1001. doi: 10.1002/ajh.24463. Epub 2016 Jul 14.

16.

The cytotoxic action of the CD56+ fraction of cytokine-induced killer cells against a K562 cell line is mainly restricted to the natural killer cell subset.

Chieregato K, Zanon C, Castegnaro S, Bernardi M, Amati E, Sella S, Rodeghiero F, Astori G.

Blood Transfus. 2017 Jan;15(1):93-100. doi: 10.2450/2016.0263-15. Epub 2016 Mar 21.

17.

Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia.

Janssens A, Rodeghiero F, Anderson D, Chong BH, Boda Z, Pabinger I, Červinek L, Terrell DR, Wang X, Franklin J.

Ann Hematol. 2016 Jun;95(7):1077-87. doi: 10.1007/s00277-016-2682-2. Epub 2016 Apr 30.

18.

Evans syndrome secondary to chronic lymphocytic leukaemia: presentation, treatment, and outcome.

Carli G, Visco C, Falisi E, Perbellini O, Novella E, Giaretta I, Ferrarini I, Sandini A, Alghisi A, Ambrosetti A, Rodeghiero F.

Ann Hematol. 2016 May;95(6):863-70. doi: 10.1007/s00277-016-2642-x. Epub 2016 Mar 22.

PMID:
27001309
19.

The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research.

Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27.

20.

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A, Rumi E, Ruggeri M, Rodeghiero F, Randi ML, Bertozzi I, Gisslinger H, Finazzi G, Carobbio A, Thiele J, Passamonti F, Falcone C, Tefferi A.

Blood Cancer J. 2015 Nov 27;5:e369. doi: 10.1038/bcj.2015.94. No abstract available.

21.

Is ITP a thrombophilic disorder?

Rodeghiero F.

Am J Hematol. 2016 Jan;91(1):39-45. doi: 10.1002/ajh.24234. Epub 2015 Nov 26. Review.

22.

Economic Assessment of Eltrombopag In The Treatment of Thrombocytopenia In Italy.

Romano F, Ruggeri M, Coretti S, Giannini EG, Sacchini D, Annicchiarico BE, Marchetti M, Rodeghiero F, Lidonnici D.

Value Health. 2015 Nov;18(7):A626. doi: 10.1016/j.jval.2015.09.2203. Epub 2015 Oct 20. No abstract available.

23.

Enumeration of residual white blood cells in leukoreduced blood products: Comparing flow cytometry with a portable microscopic cell counter.

Castegnaro S, Dragone P, Chieregato K, Alghisi A, Rodeghiero F, Astori G.

Transfus Apher Sci. 2016 Apr;54(2):266-70. doi: 10.1016/j.transci.2015.10.001. Epub 2015 Oct 22.

PMID:
26515432
24.

Economic assessment of eltrombopag in the treatment of thrombocytopenia.

Romano F, Ruggeri M, Coretti S, Giannini EG, Sacchini D, Annichiarico BE, Marchetti M, Rodeghiero F, Lidonnici D.

Expert Rev Pharmacoecon Outcomes Res. 2015;15(4):713-20. doi: 10.1586/14737167.2015.1028373.

PMID:
26176754
25.

Epstein-Barr virus DNA load in chronic lymphocytic leukemia is an independent predictor of clinical course and survival.

Visco C, Falisi E, Young KH, Pascarella M, Perbellini O, Carli G, Novella E, Rossi D, Giaretta I, Cavallini C, Scupoli MT, De Rossi A, D'Amore ES, Rassu M, Gaidano G, Pizzolo G, Ambrosetti A, Rodeghiero F.

Oncotarget. 2015 Jul 30;6(21):18653-63.

26.

Evaluation of lymphocytes inactivation by extracorporeal photopheresis using tetrazolium salt based-assay.

Chieregato K, Alghisi A, Borghero C, Elice F, Raimondi R, Zanetti E, Rodeghiero F, Astori G.

Transfus Apher Sci. 2015 Oct;53(2):242-5. doi: 10.1016/j.transci.2015.05.004. Epub 2015 May 27.

PMID:
26051797
27.

Effectiveness of lenalidomide in a patient with refractory anemia with ring sideroblasts and thrombocytosis with JAK2 (V617F) mutation.

Nichele I, Ruggeri M, Rodeghiero F.

Am J Hematol. 2015 Aug;90(8):E148-9. doi: 10.1002/ajh.24049. Epub 2015 May 28. No abstract available.

28.

Thrombotic risk in patients with immune haemolytic anaemia.

Ruggeri M, Rodeghiero F.

Br J Haematol. 2016 Jan;172(1):144-6. doi: 10.1111/bjh.13473. Epub 2015 May 5. No abstract available.

PMID:
25941063
29.

Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis.

Barbui T, Vannucchi AM, Carobbio A, Thiele J, Rumi E, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Pieri L, Pardanani A, Passamonti F, Finazzi G, Tefferi A.

Am J Hematol. 2015 May;90(5):434-7. doi: 10.1002/ajh.23970. Epub 2015 Feb 27.

30.

Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists.

Rodeghiero F, Ruggeri M.

Semin Hematol. 2015 Jan;52(1):16-24. doi: 10.1053/j.seminhematol.2014.10.006. Epub 2014 Nov 1. Review.

PMID:
25578415
31.

In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology.

Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, Randi ML, Rambaldi A, Gisslinger B, Pieri L, Bertozzi I, Casetti I, Pardanani A, Passamonti F, Vannucchi AM, Tefferi A.

Blood. 2014 Nov 6;124(19):3021-3. doi: 10.1182/blood-2014-07-591610. No abstract available.

32.

Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige? reply.

Rodeghiero F.

J Thromb Haemost. 2014 Dec;12(12):2134-6. doi: 10.1111/jth.12741. Epub 2014 Oct 25. No abstract available.

33.

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients.

Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A.

Blood. 2014 Nov 6;124(19):2930-6. doi: 10.1182/blood-2014-06-583021. Epub 2014 Sep 16.

34.

Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up.

Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Björkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, Lister A.

Br J Haematol. 2014 Dec;167(5):724-6. doi: 10.1111/bjh.13055. Epub 2014 Jul 29. No abstract available.

PMID:
25074579
35.

Von Willebrand disease.

Rodeghiero F.

Hematology. 2014 Sep;19(6):370-1. doi: 10.1179/1024533214Z.000000000292. No abstract available.

PMID:
25065290
36.

Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.

Ruggeri M, Tosetto A, Palandri F, Polverelli N, Mazzucconi MG, Santoro C, Gaidano G, Lunghi M, Zaja F, De Stefano V, Sartori R, Fazi P, Rodeghiero F; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Anemia and Thrombocytopenias Working Party. GIMEMA Study ITP0311.

J Thromb Haemost. 2014 Aug;12(8):1266-73. doi: 10.1111/jth.12636. Epub 2014 Jul 16.

37.

Diagnosing type 1 von Willebrand disease: good for patient's health or for doctor's prestige?

Rodeghiero F.

J Thromb Haemost. 2014 Aug;12(8):1234-7. doi: 10.1111/jth.12624. Epub 2014 Jun 27. No abstract available.

38.

Autoimmune cytopenias in chronic lymphocytic leukemia.

Visco C, Barcellini W, Maura F, Neri A, Cortelezzi A, Rodeghiero F.

Am J Hematol. 2014 Nov;89(11):1055-62. doi: 10.1002/ajh.23785. Epub 2014 Jul 7. Review.

39.

The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.

Federici AB, Bucciarelli P, Castaman G, Mazzucconi MG, Morfini M, Rocino A, Schiavoni M, Peyvandi F, Rodeghiero F, Mannucci PM.

Blood. 2014 Jun 26;123(26):4037-44. doi: 10.1182/blood-2014-02-557264. Epub 2014 Apr 30.

40.

Inhibitor development: The last enemy to be defeated in hemophilia A and B.

Rodeghiero F, Castaman G.

Am J Hematol. 2014 Jun;89(6):569-70. doi: 10.1002/ajh.23742. Epub 2014 Apr 26. No abstract available.

41.

Remembering professor Roberto Stasi (August 24th 1961 - January 28th 2014).

Rodeghiero F, Amadori S, Pane F.

Haematologica. 2014 Apr;99(4):794. doi: 10.3324/haematol.2014.106534. No abstract available.

42.

ITP and international guidelines: what do we know, what do we need?

Rodeghiero F, Ruggeri M.

Presse Med. 2014 Apr;43(4 Pt 2):e61-7. doi: 10.1016/j.lpm.2014.02.004. Epub 2014 Mar 20. Review.

PMID:
24656296
43.

Evidence and clinical judgment: vena cava filters.

Imberti D, Dentali F, Ageno W, Crowther M, Garcia D, Huisman M, Rodeghiero F, D'Angelo A, Palareti G.

Thromb Haemost. 2014 Apr 1;111(4):618-24. doi: 10.1160/TH13-11-0938. Epub 2014 Feb 27. Review. No abstract available.

PMID:
24573415
44.

Mortality from myelodysplastic syndromes: a multiple causes of death approach.

Fedeli U, Schievano E, Saugo M, Rodeghiero F.

Am J Hematol. 2014 Apr;89(4):450-1. doi: 10.1002/ajh.23671. Epub 2014 Feb 21. No abstract available.

45.

Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia.

Perbellini O, Falisi E, Giaretta I, Boscaro E, Novella E, Facco M, Fortuna S, Finotto S, Amati E, Maniscalco F, Montaldi A, Alghisi A, Aprili F, Bonaldi L, Paolini R, Scupoli MT, Trentin L, Ambrosetti A, Semenzato G, Pizzolo G, Rodeghiero F, Visco C.

Haematologica. 2014 May;99(5):881-7. doi: 10.3324/haematol.2013.096362. Epub 2014 Jan 10.

46.

Absence of micronucleus formation in CHO-K1 cells cultivated in platelet lysate enriched medium.

Bernardi M, Adami V, Albiero E, Madeo D, Rodeghiero F, Astori G.

Exp Toxicol Pathol. 2014 Mar;66(2-3):111-6. doi: 10.1016/j.etp.2013.11.001. Epub 2013 Nov 28.

PMID:
24290702
47.

Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C?

Visco C, Cortelezzi A, Moretta F, Falisi E, Maura F, Finotto S, Barcellini W, Ambrosetti A, Neri A, Ruggeri M, Rodeghiero F.

Leuk Lymphoma. 2014 Jun;55(6):1261-5. doi: 10.3109/10428194.2013.834054. Epub 2013 Sep 23.

PMID:
24047107
48.

Multivariate statistical data analysis as a tool to analyze ex vivo expansion dynamics of cytokine-induced killer cells.

Zanon C, Stocchero M, Albiero E, Castegnaro S, Chieregato K, Madeo D, Rodeghiero F, Astori G.

Cytometry B Clin Cytom. 2014 Jul;86(4):257-62. doi: 10.1002/cyto.b.21124. Epub 2013 Sep 3.

49.

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.

Rodeghiero F, Stasi R, Giagounidis A, Viallard JF, Godeau B, Pabinger I, Cines D, Liebman H, Wang X, Woodard P.

Eur J Haematol. 2013 Nov;91(5):423-36. doi: 10.1111/ejh.12181. Epub 2013 Sep 17.

PMID:
23927437
50.

Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice.

Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G.

Am J Hematol. 2013 Nov;88(11):955-60. doi: 10.1002/ajh.23546. Epub 2013 Sep 9.

Supplemental Content

Loading ...
Support Center